Centene Ibrutinib Prior Auth Policy Update

Coverage and Medical Necessity Criteria

Initial Approval — CLL/SLL

Covered when ALL of the following are met

CLL/SLL initial criteria: 1. Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Member must use generic ibrutinib if available unless contraindicated or clinically significant adverse effects are experienced; 5. Prescribed as a single agent or in combination with venetoclax (Venclexta); 6. Request meets one of the following dosing conditions: (a) capsules: total daily dose < 420 mg and prescribed quantity does not exceed 3 capsules per day; (b) tablets: dose is 420 mg/day and prescribed quantity does not exceed 1 tablet per day; (c) oral suspension: dose does not exceed 420 mg (6 mL) per day; or (d) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence); Prescribed regimen must be FDA‑approved or recommended by NCCN.

Initial Approval — Waldenstrom macroglobulinemia (WM)

Covered when ALL of the following are met

WM initial criteria: 1. Diagnosis of Waldenström macroglobulinemia (WM) or lymphoplasmacytic lymphoma, including symptomatic Bing‑Neel syndrome; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Member must use generic ibrutinib if available unless contraindicated or clinically significant adverse effects are experienced; 5. Prescribed as a single agent or in combination with rituximab (when specified); 6. Request meets one of the following dosing conditions: (a) capsules: total daily dose < 420 mg and prescribed quantity does not exceed 3 capsules per day; (b) tablets: dose is 420 mg/day and prescribed quantity does not exceed 1 tablet per day; (c) oral suspension: dose does not exceed 420 mg (6 mL) per day; or (d) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence); Prescribed regimen must be FDA‑approved or recommended by NCCN.

Initial Approval — cGVHD

Covered when ALL of the following are met

cGVHD initial criteria: 1. Diagnosis of chronic graft‑versus‑host disease (cGVHD); 2. Prescribed by or in consultation with an oncologist, hematologist, or bone marrow/stem cell transplant specialist; 3. History of bone marrow/stem cell transplant; 4. Member must use generic ibrutinib if available unless contraindicated or clinically significant adverse effects are experienced; 5. Member has failed BOTH of the following (unless contraindicated or clinically significant adverse effects are experienced): (a) a systemic corticosteroid at up to maximally indicated doses, and (b) a systemic immunosuppressant (see Appendix B) at up to maximally indicated doses; 6. Request meets one of the following dosing conditions: (a) capsules: total daily dose < 420 mg and prescribed quantity does not exceed 3 capsules per day; (b) tablets: dose is 420 mg/day and prescribed quantity does not exceed 1 tablet per day; (c) oral suspension: dose does not exceed 420 mg (6 mL) per day; (d) for age 1 to <12 years, oral suspension dosing referenced as 240 mg/m^2 per day; or (e) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence); Note: Imbruvica should not be prescribed concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil).

Initial Approval — NCCN Compendium Indications (Off‑label)

Covered when ALL of the following are met

NCCN compendium indications: 1. Diagnosis consistent with NCCN Compendium B‑cell malignancy indications (examples include primary CNS lymphoma; brain metastases in lymphoma; hairy cell leukemia [HCL] with disease progression after prior therapy; post‑transplant lymphoproliferative disorder [PTLD]; high‑grade B‑cell lymphoma; diffuse large B‑cell lymphoma [DLBCL]; mantle cell lymphoma [MCL]; marginal zone lymphoma [MZL] subtypes with relapsed/refractory/progressive disease; and histologic transformation of CLL/SLL to DLBCL in patients with del(17p)/TP53 mutation when combined with Opdivo or Keytruda where specified); 2. Age > 18 years unless the specific indication allows pediatric use per policy; 3. Prescribed by or in consultation with an oncologist or hematologist; 4. Member must use generic ibrutinib if available unless contraindicated or clinically significant adverse effects are experienced; 5. Member meets any indication‑specific subcriteria (e.g., prior lines of therapy, role as induction or maintenance, combination with rituximab for MCL when specified); 6. For oral suspension requests at a dose of 420 mg/day, documentation supports inability to swallow capsules/tablets; 7. Request meets one of the following dosing conditions: (a) capsules: total daily dose < 420 mg and prescribed quantity does not exceed 3 capsules per day; (b) tablets: dose is 420 mg/day and prescribed quantity does not exceed 1 tablet per day; (c) oral suspension: dose does not exceed 420 mg (6 mL) per day; or (d) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence); Prescribed regimen must be FDA‑approved or recommended by NCCN.

Initial therapy — Initial therapy criteria vary by indication and must all be met for approval

Initial therapy criteria vary by indication and must all be met for approval

Initial therapy by indication: See separate initial criteria sets for CLL/SLL, WM, cGVHD, and NCCN compendium indications which include prescriber specialty, age requirements, use of generic ibrutinib when available, dosing limits (tablets 420 mg/day; capsules ≤3/day; oral suspension ≤420 mg/day) and any indication‑specific prior therapy requirements (e.g., cGVHD requires prior trial of systemic corticosteroid and systemic immunosuppressant).

Approval durations: Medicaid/HIM typically 6 months for initial approvals; Commercial typically 12 months or duration of request, whichever is less.

Initial therapy requirements — Initial therapy notes and prior trial requirements referenced in revisions

Initial therapy notes and prior trial requirements: cGVHD initial therapy requires trial of both a systemic corticosteroid and a systemic immunosuppressant per NCCN and the Imbruvica pivotal trial; documentation of prior therapies and reasons for contraindication or intolerance must be provided when applicable; for oral suspension requests at 420 mg/day, documentation of inability to swallow capsules/tablets is required.

These requirements were added/clarified in prior P&T reviews (1Q2021 and 1Q2023) and reflected in Appendix B.

Continuation Therapy

Covered when ALL of the following are met

Continuation therapy: 1. Documentation supports member is currently receiving ibrutinib for a covered oncology‑related indication and has received the medication for at least 30 days; 2. Member is responding positively to therapy; 3. Member must use generic ibrutinib if available unless contraindicated or clinically significant adverse effects are experienced; 4. Imbruvica is not prescribed concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil) for cGVHD patients; 5. If request is for a dose increase, the new dose must meet dosing limit criteria (capsules < 420 mg/day and ≤3 capsules/day; tablets 420 mg/day and ≤1 tablet/day; oral suspension ≤420 mg [6 mL]/day) or be supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).

Approval durations for continuation: Medicaid/HIM typically 12 months; Commercial approvals typically 12 months or duration of request, whichever is less.

Continuation therapy — Continuation therapy requirements for ongoing coverage

Continuation therapy requirements for ongoing coverage

Continuation therapy operational criteria: Member has been receiving ibrutinib for at least 30 days; member is demonstrating clinical benefit (responding positively); continued use of generic product when available unless contraindicated; dosing remains within allowed limits or any dose increases are supported by guidelines or literature; for oral suspension continuation at 420 mg/day, ongoing documentation of inability to swallow capsules/tablets is required; for cGVHD, avoid concurrent use with Jakafi or Rezurock.

Continuation therapy — Authorization/approval duration and continuation considerations noted in policy history

Authorization/approval duration and continuation considerations noted in policy history

Continuation/renewal durations: Commercial prior authorization approvals are generally limited to 12 months or the duration of the request, whichever is less; Medicaid/HIM continuation/initial durations noted in policy history (typical Medicaid/HIM initial approvals historically 6 months; continuation frequently set to 12 months).

These duration changes and pediatric/oral suspension template updates are documented in policy history.

Notable coverage criteria updates and indication clarifications

Coverage is provided when criteria aligned with FDA labeling and NCCN guidance are met; notable recent criteria updates include:

CLL/SLL updates: Per 1Q 2025, combination use with venetoclax (Venclexta) was added for CLL/SLL; for histologic transformation of CLL/SLL to DLBCL coverage requires combination with PD‑1 inhibitors (Opdivo or Keytruda) in specified patients (e.g., del(17p)/TP53 mutation).

From P&T and policy revision history.

Waldenstrom's Macroglobulinemia (WM): Lymphoplasmacytic lymphoma was added to WM criteria and coverage clarified to include symptomatic Bing‑Neel syndrome only.

From NCCN‑aligned updates.

MZL nomenclature and requirements: Replaced Gastric/Nongastric MALT terminology with Extranodal MZL (noncutaneous) and for Nodal and Extranodal MZL added requirement for relapsed, refractory, or progressive disease to meet coverage criteria.

From 1Q 2025 update.

Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider submits sufficient documentation of efficacy and safety in line with applicable off‑label use policies. For Commercial plans refer to CP CPA.09, for Health Insurance Marketplace plans refer to HIM.PA.154, and for Medicaid refer to CPP M N.53 (or the state evidence of coverage documents) to support off‑label requests.

Per the 1Q 2023 review, the policy no longer authorizes combination use of ibrutinib with rituximab (Rituxan), obinutuzumab (Gazyva), or bendamustine for CLL/SLL; these combination regimens were removed from the CLL/SLL coverage recommendations.

Off‑label uses not covered by FDA labeling may be considered only when supported by adequate evidence and documentation. Requests for non‑FDA indications must include clinical rationale and supporting literature or guideline citations demonstrating efficacy and safety per the referenced off‑label policies. Additionally, recent policy updates clarified compendium indications and exclusions (for example, removal of certain NCCN‑listed uses and the addition of specific lymphoma subtypes), so providers should reference the current NCCN recommendations and include that supporting documentation when requesting coverage for an off‑label indication.

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Imbruvica (ibrutinib). Providers must submit a prior authorization request that demonstrates the member meets the applicable diagnosis-specific clinical criteria and includes the prescriber specialty when required (e.g., oncology, hematology, or bone marrow transplant specialist for cGVHD). Commercial approvals are generally limited to 12 months or the duration of the request, whichever is less; Medicaid duration follows state-specific provisions.

Prescriber specialty must be documented when specified in the criteria (oncologist, hematologist, or bone marrow transplant specialist for cGVHD).
Commercial approval duration: 12 months or duration of request, whichever is less.
Medicaid: follow state Medicaid manual if state provisions conflict.

Documentation Required

Provider must submit supporting clinical documentation with the prior authorization request. Acceptable documentation includes office chart notes, relevant laboratory and pathology results, imaging reports, prior treatment records, and any peer-reviewed literature or guideline citations supporting off-label dosing or use. For cGVHD requests, documentation must show trials of both a systemic corticosteroid and a systemic immunosuppressant at up to maximally indicated doses unless contraindicated or not tolerated. Failure to submit required documentation may result in denial of the request.

Dosing Limits, Formulations, and Quantity Guidance

Tablet / capsule / oral suspension dosing limits

Tablet maximum420 mg per day (prescribed quantity does not exceed 1 tablet/day)

Capsule maximumLess than 420 mg per day; prescribed quantity does not exceed 3 capsules/day

Oral suspension maximumDoes not exceed 420 mg (6 mL) per day; documentation required for inability to swallow capsules/tablets

Pediatric cGVHD dosingFor age 1 to <12 years: 240 mg/m2 per day (up to a maximum of 420 mg/day)

Ibrutinib — Quantity limit

Quantity limit (daily)420 mg per day

Required Prior Trials and Step Therapy

Required prior therapy for cGVHD before ibrutinib
Failure of a systemic corticosteroid at up to maximally indicated doses (unless contraindicated or clinically significant adverse effects)
Failure of a systemic immunosuppressant at up to maximally indicated doses (unless contraindicated or clinically significant adverse effects)

Prior trial of both agent classes prior to approval
Policy edited to require a trial of both a systemic corticosteroid and a systemic immunosuppressant agent per NCCN and the pivotal Imbruvica trial before approval for cGVHD
Imbruvica should not be prescribed concurrently with Jakafi (ruxolitinib) or Rezurock (belumosudil) for cGVHD; documentation of prior trials is required unless contraindicated

Step Therapy

cGVHD prior therapy (cross‑reference) — trial of corticosteroid and immunosuppressant required

Cross-reference: the cGVHD requirement specifies that both a systemic corticosteroid and a systemic immunosuppressant must be tried and documented prior to approval, per NCCN and the policy revisions.

Document both prior corticosteroid and immunosuppressant trials in the medical record and include them with the authorization request.

Terms, Appendix References, and Therapeutic Alternatives

BTK — Definition

TermBTK

DefinitionBruton's tyrosine kinase

ContextBTK is the drug class targeted by ibrutinib (a BTK inhibitor)

cGVHD — Definition

TermcGVHD

Definitionchronic graft-versus-host disease

ContextReferenced in indications and pediatric dosing guidance within the policy

Background and Drug Overview

Ibrutinib (Imbruvica) is an oral Bruton’s tyrosine kinase (BTK) inhibitor indicated for multiple B‑cell malignancies and for chronic graft‑versus‑host disease (cGVHD). The policy maps FDA‑approved indications and NCCN compendium uses to specific prior authorization requirements, including prescriber specialty, age limits, dosing and formulation limits (common adult dosing 420 mg/day and oral suspension parameters), and required prior therapy for cGVHD (trial of a systemic corticosteroid and a systemic immunosuppressant). Documentation (office notes, labs, or guideline citations) must be submitted to demonstrate the member meets the applicable approval criteria.

Policy Changes and History

2025-02-25P&T update / NCCN alignmentLatest

Per 1Q 2025 annual review, policy updated to add combination use with venetoclax (Venclexta) for CLL/SLL, require combination with PD‑1 inhibitors (Opdivo or Keytruda) for histologic transformation of CLL/SLL to DLBCL, and revised MZL nomenclature and relapsed/refractory requirement; references reviewed and updated.

2024-02-24Annual review — clinical clarifications

1Q 2024 review clarified coverage for symptomatic Bing‑Neel syndrome only, added off‑label coverage criteria for brain metastases in lymphoma, limited HCL use to disease progression after prior therapy, and updated related references.

OpenPayer

Clinical Policy: Ibrutinib (Imbruvica)

Coverage and Medical Necessity Criteria

Prior Authorization, Documentation, and Provider Requirements

Dosing Limits, Formulations, and Quantity Guidance

Required Prior Trials and Step Therapy

Terms, Appendix References, and Therapeutic Alternatives

Background and Drug Overview

Policy Changes and History